Study of Metronomic Capecitabine and Oxaliplatin Versus XELOX in Egyptian Metastatic Colorectal Cancer Patients

Colorectal cancer (CRC) in Egypt is advanced tumors at diagnosis. Although, the dramatic increase in efficacy, reduction of mortality, and improvements in survival by the use of standard doses of chemotherapy, some CRC patients suffer from severe toxicities besides disease progression. Use of chemotherapy less than the maximum tolerated dose, with no prolonged drug free breaks incapacitates the cells to engage in progression mechanisms, suggesting that it could be a better alternative to standard dose therapy with better toxicity profile

埃及的结直肠癌（colorectal cancer, CRC）患者确诊时多已处于晚期肿瘤阶段。尽管标准剂量化疗可显著提升治疗疗效、降低死亡率并改善患者生存期，但部分结直肠癌患者不仅会出现疾病进展，还会遭受严重的毒副反应。若采用低于最大耐受剂量的化疗方案且不设置延长的无药间歇期，将使肿瘤细胞无法激活进展相关机制，这提示该方案或可成为标准剂量治疗的更优替代选择，且毒副反应谱更为温和。